Adjuvant therapy for localized prostate cancer.

Abstract

BACKGROUND:

In 1978, the National Prostatic Cancer Project launched two protocols evaluating adjuvant therapy after surgery (Protocol 900) or irradiation (Protocol 1000) for clinically localized prostate cancer. All patients underwent staging pelvic lymphadenectomy.

METHODS:

After definitive treatment, the patients were randomized either to receive cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years or estramustine phosphate 600 mg/m2 orally daily for up to 2 years or to undergo observation only. Patient accession closed in 1985 and includes 184 patients in Protocol 900 (170 evaluable) and 253 in Protocol 1000 (233 evaluable).

RESULTS:

Lymph node involvement was identified in 198 patients (49% of total), 29% in Protocol 900 and 63% in Protocol 1000. The median progression-free survival (PFS) and survival were greater for patients in Protocol 900 compared with 1000, regardless of the adjuvant therapy. This reflected the greater proportion of patients with lower pathologic stage disease in the surgically treated group. The median PFS was significantly greater for all patients in Protocol 1000 receiving estramustine phosphate adjuvant (48.2 months) compared with patients randomized to receive cyclophosphamide (35.6 months). The median PFS for patients with nodal involvement in Protocol 1000 who received estramustine phosphate adjuvant was prolonged significantly (37.3 months) compared with no treatment (20.9 months). The median PFS for patients with limited nodal disease in Protocol 1000 was longer (39.9 months), regardless of the adjuvant therapy, compared with those with extensive nodal disease (20.7 months). However, in the latter patient group, those receiving adjuvant estramustine phosphate had a significantly longer median PFS (32.8 months) compared with those receiving adjuvant cyclophosphamide (22.7 months) or no adjuvant therapy (12.9 months).

CONCLUSION:

Adjuvant estramustine phosphate was beneficial in patients with prostate cancer and pelvic node involvement who received irradiation as definitive treatment.

• Authors: J D Schmidt, R P Gibbons, G P Murphy, A Bartolucci
• Journal: Cancer (Cancer) Vol. 71 Issue 3 Suppl Pg. 1005-13 (Feb 01 1993) ISSN: 0008-543X [Print] United States
• PMID: 8428323 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Estramustine
• Cyclophosphamide

Topics

• Chemotherapy, Adjuvant
• Cyclophosphamide (administration & dosage)
• Drug Administration Schedule
• Estramustine (administration & dosage)
• Humans
• Incidence
• Lymphatic Metastasis
• Male
• Neoplasm Recurrence, Local (epidemiology)
• Neoplasm Staging
• Prospective Studies
• Prostatic Neoplasms (drug therapy, mortality, pathology, radiotherapy, surgery)
• Survival Analysis